Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site. # Recombinant Antibody Network The Recombinant Antibody Network is a consortium of highly integrated technology centers ## Sitemaps - [XML Sitemap](https://recombinant-antibodies.org/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [News](https://recombinant-antibodies.org/news/) - News - [Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies](https://recombinant-antibodies.org/recombinant-antibody-network-partners-with-bristol-myers-squibb-to-develop-novel-therapies/) - The Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, has entered into a second research collaboration with Celgene that aims to create and develop high-performance recombinant antibodies against diverse targets in human cells. The first RAN collaboration was launched in 2015 - [Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies](https://recombinant-antibodies.org/absolute-antibody-partners-with-the-recombinant-antibody-network-to-facilitate-access-to-engineered-recombinant-antibodies/) - Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced a partnership with the Recombinant Antibody Network (RAN), a consortium of three expert centers at the University of Chicago, University of Toronto, and UC San Francisco (UCSF) with a common goal to generate recombinant antibodies at a proteome-wide scale. Under the - [RAN to collaborate with Celgene on cancer therapeutics development](https://recombinant-antibodies.org/ran-to-collaborate-with-celgene-on-cancer-therapeutics-development/) - The RAN has recently signed a 3-year $25M agreement with the Celgene Corporation to develop next-generation, antibody-based cancer therapies with the option to enter into future license agreements. Collaboration will focus on novel high value cancer targets. Besides supporting the high throughput antibody generating pipelines, this agreement will enable setting up robotics for a battery of state - ['IP gold standard' antibodies for select chromatin-related human proteins developed](https://recombinant-antibodies.org/ip-gold-standard-antibodies-for-select-chromatin-related-human-proteins-developed/) - We have established a collection 'IP gold standard' antibodies in the tour de force study of 1,124 new recombinant antibodies for 152 chromatin-related human proteins. This set is accomapnied with a collection of SOPs which can be accesed here rdcu.be/dfUd. - [849 rABs in our catalog!](https://recombinant-antibodies.org/852-rabs-in-our-catalog/) - We have recently updated the antibody catalog with new antibody binders that are made available by the Recombinant Antibody Network. There are currently 849 binders available in the catalog. - [New binders added to antibody catalog](https://recombinant-antibodies.org/new-binders-added-to-antibody-catalog/) - We have recently updated the antibody catalog with new antibody binders that are made available by the Recombinant Antibody Network. There are currently 495 binders available in the catalog. - [Automated antibody phage display selection and screening system](https://recombinant-antibodies.org/automated-antibody-phage-display-selection-and-screening-system/) - Advanced robotic system designed to screen thousands of recombinant antibodies without human intervention. Video shows sequence of ELISA and colony picking schedules executed on the same system. Portions of this video has been speed up by a factor of 2. - [UCSF RAN Node Receives QB3 funds to explore alternative protein expression platforms](https://recombinant-antibodies.org/ucsf-ran-node-receives-qb3-funds-to-explore-alternative-protein-expression-platforms/) - In December 2012 the UCSF node of the RAN received funding from the California Instituet for Quantitative Biosciences (QB3) to kickstart the development of two automated protein expression pipelines designed to suppliment the RAN antigen needs. - [RAN: A proven track record for collaboration](https://recombinant-antibodies.org/ran-a-proven-track-record-for-collaboration/) - A major strength of the management structure is the proven record of the leadership to work in unison to manage large, complex and intellectually challenging programs. In fact, several of the team have successfully managed projects in industry that were significantly larger and more complex than what is proposed here. Further, the RAN leadership team - [New targets added to the LIMS](https://recombinant-antibodies.org/new-targets-added-to-the-lims/) ## Pages - [Home](https://recombinant-antibodies.org/) - Welcome to the Recombinant Antibody Network The Recombinant Antibody Network is a consortium of highly integrated technology centers at UCSF, the University of Chicago, and the University of Toronto, unified under a common goal to generate therapeutic grade recombinant antibodies at a proteome wide scale for biology and biomedicine.Given that over half the human proteome - [Publications: 2026](https://recombinant-antibodies.org/publications/publications-2026/) - Publications: 2026 - [About the RAN](https://recombinant-antibodies.org/about-us/) - About the RANThe Recombinant Antibody Network is an international consortium of three expert centers at the University of Chicago, University of Toronto, and the University of California at San Francisco (UCSF) unified under a common set of goals, technologies, and operational procedures. The multi-site rAB generation and validation approach has many advantages, including:Each site brings - [Protocols](https://recombinant-antibodies.org/protocols/) - Protocols rAB expression and purificationrAB validation pSFV4-Avi IPTG-based Biotinylated rAB ExpressionpFab007 PhoA-based rAB expressionpBL166 IPTG-based rAB ExpressionRH2.2 IPTG-based rAB ExpressionRH2.2 IPTG-based Biotinylated rAB ExpressionFAQ: Expression and Purification pSFV4-Avi IPTG-based Biotinylated rAB Expression Expression and purification of biotinylated rAB’s cloned into the pSFV4 expression vector with a Heavy Chain Avi Biotinylation tag. 1.0 Introduction This method - [Contact Us](https://recombinant-antibodies.org/contact-us/) - Contact Us Send Message First Name Last Name Email Subject Message Send MessageThe form has been submitted successfully!There has been some error while submitting the form. Please verify all form fields again. The University of ChicagoKnapp Center for Biomedical Discovery Rm. 3240G900 E. 57th St., Chicago, IL 60637Phone: +1 (773) 834-2776 University of California, San FranciscoByers - [Technologies](https://recombinant-antibodies.org/technologies/) - These powerful capabilities open a multitude of opportunities for studying complex macromolecular processes at a level inaccessible to current technology. These attributes are particularly relevant to the task of generating “ChIP-able” rAB affinity reagents to the human TFs. TFs are flexible multidomain proteins that generally function bound to DNA and in the context of larger - [Publications](https://recombinant-antibodies.org/publications/) - Publications View by year Search Search for author, keywords, or any other term. - [Publications: 2018](https://recombinant-antibodies.org/publications/publications-2018/) - Publications: 2018 - [Publications: 2012](https://recombinant-antibodies.org/publications/publications-2012/) - Publications: 2012 - [Publications: 2014](https://recombinant-antibodies.org/publications/publications-2014/) - Publications: 2014 - [Publications: 2013](https://recombinant-antibodies.org/publications/publications-2013/) - Publications: 2013 - [Publications: 2015](https://recombinant-antibodies.org/publications/publications-2015/) - Publications: 2015 - [Publications: 2017](https://recombinant-antibodies.org/publications/publications-2017/) - Publications: 2017 - [Publications: 2016](https://recombinant-antibodies.org/publications/publications-2016/) - Publications: 2016 - [Publications: 2019](https://recombinant-antibodies.org/publications/publications-2019/) - Publications: 2019 - [Publications: 2020](https://recombinant-antibodies.org/publications/publications-2020/) - Publications: 2020 - [Publications: 2021](https://recombinant-antibodies.org/publications/publications-2021/) - Publications: 2021 - [Publications: 2022](https://recombinant-antibodies.org/publications/publications-2022/) - Publications: 2022 - [Publications: 2023](https://recombinant-antibodies.org/publications/publications-2023/) - Publications: 2023 - [Publications: 2024](https://recombinant-antibodies.org/publications/publications-2024/) - Publications: 2024 - [Publications: 2025](https://recombinant-antibodies.org/publications/publications-2025/) - Publications: 2025 - [Material Request](https://recombinant-antibodies.org/material-request/) - Material Request Please fill out the following form for the requested materials. We will then send you a form, which we ask you to fill out, sign, and return to us. - [Terms of Use](https://recombinant-antibodies.org/terms-of-use/) - Terms of Use The Recombinant Antibody Network (RAN) provides all its content on an “as is” basis, without warranty or representation of any kind, express or implied. You may download material from the site for your personal, non-commercial use only, provided that you keep intact all authorship, copyright and other proprietary notices. If you use - [Antibody Catalog](https://recombinant-antibodies.org/catalog/) - Antibody Catalog Our antigens are organized by HGNC names which can be looked up at https://www.genenames.org/. Search by approved symbol or antigen synonyms to list available antibodies. - [Search](https://recombinant-antibodies.org/search/) - Search ## Categories - [news](https://recombinant-antibodies.org/category/news/)